Black Diamond to present silevertinib data at ASCO meeting

Black Diamond Therapeutics will present multiple silevertinib data readouts at ASCO from May 29 to June 2, including Phase 2 results in treatment-naive and previously treated NSCLC and a trial-in-progress poster in EGFRvIII-positive glioblastoma. The company also reiterated plans to start a randomized Phase 2 GBM study in Q2 2026, following December 2025 Phase 2 data that showed a 60% objective response rate in frontline NSCLC patients with non-classical EGFR mutations. Freedom Capital Markets raised its price target to $7 from $6 and maintained a Buy rating, reinforcing a positive but still highly speculative biotech setup.

Analysis

BDTX is trading more like a data readout optionality vehicle than a conventional biotech, so the key question is not whether the upcoming ASCO set is “good,” but whether it is good enough to re-rate the probability of a partnering event before the company has to fund the next leg of development. With a sub-$200M equity value, even modest clinical de-risking can matter disproportionately because the stock is still pricing a non-trivial chance that the program is real but not yet commercially shapeable; that makes the June conference window a potential volatility amplifier rather than a clean fundamental catalyst.

The second-order effect is that the most important competitive comparison may be against other EGFR mutation programs that are easier to sell into large pharma, not against standard NSCLC names. If silevertinib continues to show activity in the non-classical and C797S subsets, it strengthens a “mutation-franchise” narrative that can support partnerships across lung and CNS, which is far more valuable than a single-tumor readthrough; however, that same breadth also raises execution risk because the market will demand proof that the CNS angle is not just scientific garnish.

The setup is asymmetric into the event but fragile afterward. The main tail risk is not a weak headline ORR; it is a narrower-than-expected durability signal, modest differentiation versus incumbent EGFR approaches, or data that look better in presentation format than in investable commercial terms. Over 1-3 months, the stock could rerate sharply on a partnerable package; over 6-12 months, the key reversal risk is dilution if the company must self-fund expansion before a deal lands.

Key Decisions for Investors

• Trade the event, not the story: initiate a small pre-ASCO long in BDTX via equity or calls into the late-May presentation window, with a hard exit if the oral data fail to extend durability/differentiation versus the prior cutoff; target a 1.5-2.0x move on a clean readout, but size for binary biotech volatility.
• Use a call spread rather than stock if entering fresh: buy BDTX June/September upside calls and finance part of the premium with higher strikes to cap theta decay; this keeps exposure to a partnership or momentum chase while limiting damage if the market sells the print.
• Pair idea: long BDTX vs. short a basket of higher-quality large-cap oncology names as a catalyst-driven relative-value trade only through ASCO; the upside comes from idiosyncratic re-rating, while the short leg reduces market beta if risk appetite fades.
• If the ASCO data are strong, shift from event-trade to follow-through trade only on confirmation of partnering language or trial expansion; absent that, treat any post-data spike as a liquidity opportunity and reduce exposure into strength.
• Avoid holding an oversized position through the full conference if the fund cannot tolerate 20-30% gap risk; the name’s volatility means the best risk/reward is usually a defined-risk options structure rather than an outright cash equity bet.